Estuary Biotherapeutics emerges with $103 million for kidney disease gene therapies
Estuary Biotherapeutics, a California-based biotech developing gene therapies for kidney disease, officially launched with $103 million in funding and a management team of former Biogen leaders backed by investors including Biogen.
